CL2017001640A1 - Terapia con antagonista del receptor de oxitocina en la fase lútea para la implantación y embarazo en mujeres que se someten a tecnologías de reproducción asistida. - Google Patents
Terapia con antagonista del receptor de oxitocina en la fase lútea para la implantación y embarazo en mujeres que se someten a tecnologías de reproducción asistida.Info
- Publication number
- CL2017001640A1 CL2017001640A1 CL2017001640A CL2017001640A CL2017001640A1 CL 2017001640 A1 CL2017001640 A1 CL 2017001640A1 CL 2017001640 A CL2017001640 A CL 2017001640A CL 2017001640 A CL2017001640 A CL 2017001640A CL 2017001640 A1 CL2017001640 A1 CL 2017001640A1
- Authority
- CL
- Chile
- Prior art keywords
- women
- pregnancy
- implantation
- increase
- assisted reproduction
- Prior art date
Links
- 230000035935 pregnancy Effects 0.000 title abstract 3
- 238000005516 engineering process Methods 0.000 title abstract 2
- 229940122828 Oxytocin receptor antagonist Drugs 0.000 title 1
- 238000002513 implantation Methods 0.000 title 1
- 230000029849 luteinization Effects 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 239000005557 antagonist Substances 0.000 abstract 2
- 210000002257 embryonic structure Anatomy 0.000 abstract 2
- 210000001161 mammalian embryo Anatomy 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/42—Gynaecological or obstetrical instruments or methods
- A61B17/425—Gynaecological or obstetrical instruments or methods for reproduction or fertilisation
- A61B17/435—Gynaecological or obstetrical instruments or methods for reproduction or fertilisation for embryo or ova transplantation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Surgery (AREA)
- Gynecology & Obstetrics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pregnancy & Childbirth (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Medical Informatics (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicinal Preparation (AREA)
Abstract
<p>LA PRESENTE INVENCIÓN SE RELACIONA CON EL USO DE UN ANTAGONISTA DEL RECEPTOR DE OXITOCINA EN MUJERES QUE SE SOMETEN A LA TRANSFERENCIA DE EMBRIONES COMO PARTE DE UNA TECNOLOGÍA DE REPRODUCCIÓN ASISTIDA. EN PARTICULAR, SE PROPORCIONAN MÉTODOS PARA AUMENTAR LA TASA DE IMPLANTACIÓN EN CURSO, AUMENTO DE LA TASA DE EMBARAZO EN CURSO, AUMENTO DE LA TASA DE EMBARAZO, Y/O AUMENTO DE LA TASA DE NACIDOS VIVOS EN UN SUJETO FEMENINO SOMETIDO A LA TRANSFERENCIA DE EMBRIONES. ESPECÍFICAMENTE, LOS ANTAGONISTAS SE LIBERAN EN LA FASE LÚTEA CUANDO EL ENDOMETRIO ESTA RECEPTIVO PARA LA IMPLANTACIÓN DE EMBRIONES Y/O CUANDO EL EMBRIÓN HA ALCANZADO EL ESTADIO DE BLASTOCITO.</p>
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14199709.8A EP3037101B1 (en) | 2014-12-22 | 2014-12-22 | Oxytocin receptor antagonist therapy in the luteal phase for implantation and pregnancy in women undergoing assisted reproductive technologies |
| US14/643,307 US9579305B2 (en) | 2014-12-22 | 2015-03-10 | Oxytocin receptor antagonist therapy in the luteal phase for implantation and pregnancy in women undergoing assisted reproductive technologies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2017001640A1 true CL2017001640A1 (es) | 2018-01-26 |
Family
ID=52338895
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2017001640A CL2017001640A1 (es) | 2014-12-22 | 2017-06-21 | Terapia con antagonista del receptor de oxitocina en la fase lútea para la implantación y embarazo en mujeres que se someten a tecnologías de reproducción asistida. |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US9579305B2 (es) |
| EP (2) | EP3501533B1 (es) |
| JP (2) | JP6858130B2 (es) |
| KR (1) | KR102715569B1 (es) |
| CN (2) | CN113940990A (es) |
| AU (1) | AU2015367900B2 (es) |
| BR (1) | BR112017013521A2 (es) |
| CA (1) | CA2971846A1 (es) |
| CL (1) | CL2017001640A1 (es) |
| EA (1) | EA201791361A1 (es) |
| ES (2) | ES3041573T3 (es) |
| IL (1) | IL253078B (es) |
| MX (1) | MX374877B (es) |
| MY (1) | MY181349A (es) |
| PH (1) | PH12017550030B1 (es) |
| PL (1) | PL3037101T3 (es) |
| SG (1) | SG11201705175RA (es) |
| TW (1) | TWI702043B (es) |
| UA (1) | UA125492C2 (es) |
| WO (1) | WO2016105190A1 (es) |
| ZA (1) | ZA201704958B (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2845850A1 (en) | 2013-09-10 | 2015-03-11 | ObsEva S.A. | Pyrrolidine derivatives as oxytocin/vasopressin V1a receptors antagonists |
| EP2886107A1 (en) | 2013-12-17 | 2015-06-24 | ObsEva S.A. | Oral formulations of pyrrolydine derivatives |
| KR102470283B1 (ko) | 2014-07-02 | 2022-11-23 | 옵스에파 에스에이 | 결정질 (3z,5s)-5-(하이드록시메틸)-1-[(2'-메틸-1,1'-바이페닐-4-일)카르보닐]피롤리딘-3-온 o-메틸옥심 |
| PL3037101T3 (pl) | 2014-12-22 | 2019-06-28 | Ferring B.V. | Terapia antagonistą receptora oksytocyny w fazie lutealnej w celu implantacji i uzyskania ciąży u kobiet poddawanych technikom wspomaganego rozrodu |
| SMT202200248T1 (it) | 2016-01-04 | 2022-07-21 | ObsEva SA | Cosomministrazione di alfa-ammino estere di derivato di idrossipropiltiazolidina carbossammide e un agente tocolitico |
| CA3031252A1 (en) * | 2016-07-21 | 2018-01-25 | ObsEva S.A. | Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage |
| JP7584201B2 (ja) | 2019-09-03 | 2024-11-15 | オブセヴァ エス．エー． | 薬学的組成物 |
| US20230102503A1 (en) | 2020-02-10 | 2023-03-30 | ObsEva S.A. | Biomarkers for oxytocin receptor antagonist therapy |
| EP4238579A4 (en) * | 2020-10-28 | 2024-04-24 | National University Corporation Tokai National Higher Education and Research System | THERAPEUTIC AGENT FOR MALIGNANT MESOTHELIOMA AND METHOD FOR SELECTING A PATIENT WITH MALIGNANT MESOTHELIOMA |
| CN114292907A (zh) * | 2020-12-15 | 2022-04-08 | 苏州亿康医学检验有限公司 | 用于反复植入失败的生物标志物和诊断与治疗方法 |
| CN117531006B (zh) * | 2023-10-10 | 2025-02-11 | 山东奥克斯畜牧种业有限公司 | 一种提高牛胚胎移植受胎率的组合制剂及其制备方法与应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9604341D0 (sv) * | 1996-11-26 | 1996-11-26 | Ferring Bv | Hepta-peptide oxytocin analogue |
| AUPP421298A0 (en) | 1998-06-19 | 1998-07-09 | Fertilitescentrum Ab | Method and medium for in vitro culture of human embryos |
| ES2290284T3 (es) * | 2001-01-09 | 2008-02-16 | Bayer Schering Pharma Aktiengesellschaft | El uso de antigestagenos para inhibir la maduracion endometrial acelerada durante el tratamiento de infertilidad. |
| DE60238490D1 (de) * | 2001-09-12 | 2011-01-13 | Merck Serono Sa | Verwendung von humanem choriongonadotropin (hcg) und luteinisierendem hormon (lh) zur regulierten hyperstimulation der eierstöcke |
| EP1480998B1 (en) | 2002-02-27 | 2006-11-22 | Ferring BV | Intermediates and methods for making heptapeptide oxytocin analogues |
| UA78058C2 (en) * | 2002-07-05 | 2007-02-15 | Applied Research Systems | Pyrrolidine derivative as oxitocin antagonists |
| GB0219961D0 (en) | 2002-08-28 | 2002-10-02 | Pfizer Ltd | Oxytocin inhibitors |
| FR2849380A1 (fr) * | 2002-12-27 | 2004-07-02 | Ernest Loumaye | NOUVELLE UTILISATION D'UN AGONISTE DU GnRH |
| US7111275B2 (en) | 2003-08-28 | 2006-09-19 | International Business Machines Corporation | Electronic circuit design analysis system |
| US20070276019A1 (en) | 2003-09-18 | 2007-11-29 | Axys Pharmaceuticals, Inc. | Haloalkyl Containing Compounds as Cysteine Protease Inhibitors |
| WO2005028452A1 (en) | 2003-09-22 | 2005-03-31 | Pfizer Limited | Substituted triazole derivatives as oxytocin antagonists |
| EP1555029A1 (en) | 2004-01-19 | 2005-07-20 | Ferring B.V. | Use of substances having oxytocin antagonistic properties for the preparation of a medicament for treating hypertension |
| WO2006121362A2 (en) * | 2005-05-10 | 2006-11-16 | Ferring International Center Sa. | Use of antagonists of oxytocin and/or vasopressin in assisted reproduction |
| WO2010010201A1 (es) | 2008-07-22 | 2010-01-28 | Equipo Ivi Investigacion Sl | Perfil de expresion genetica como marcador de la receptividad endometrial |
| EP2430154A4 (en) | 2009-05-14 | 2014-01-08 | Adelaide Res & Innovation Pty | METHOD FOR REMOVING AND RINSING OOCYTES |
| WO2013004612A1 (en) | 2011-07-01 | 2013-01-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for determining developmental stage of human cumulus cells |
| US10271876B2 (en) | 2011-11-23 | 2019-04-30 | Mezadata Medical Ip Holding Llc | Method of in vitro fertilization with delay of embryo transfer and use of peripheral blood mononuclear cells |
| WO2013181549A2 (en) | 2012-05-31 | 2013-12-05 | Auxogyn, Inc. | In vitro embryo blastocyst prediction methods |
| US20160278688A1 (en) | 2012-11-26 | 2016-09-29 | Ferring B.V. | Method and System for Diagnosing Uterine Contraction Levels Using Image Analysis |
| PL3037101T3 (pl) | 2014-12-22 | 2019-06-28 | Ferring B.V. | Terapia antagonistą receptora oksytocyny w fazie lutealnej w celu implantacji i uzyskania ciąży u kobiet poddawanych technikom wspomaganego rozrodu |
-
2014
- 2014-12-22 PL PL14199709T patent/PL3037101T3/pl unknown
- 2014-12-22 ES ES19153560T patent/ES3041573T3/es active Active
- 2014-12-22 EP EP19153560.8A patent/EP3501533B1/en active Active
- 2014-12-22 EP EP14199709.8A patent/EP3037101B1/en active Active
- 2014-12-22 ES ES14199709T patent/ES2716862T3/es active Active
-
2015
- 2015-03-10 US US14/643,307 patent/US9579305B2/en active Active
- 2015-12-18 TW TW104142629A patent/TWI702043B/zh active
- 2015-12-21 MY MYPI2017702341A patent/MY181349A/en unknown
- 2015-12-21 CA CA2971846A patent/CA2971846A1/en active Pending
- 2015-12-21 US US15/538,639 patent/US10688106B2/en active Active
- 2015-12-21 CN CN202111236155.1A patent/CN113940990A/zh active Pending
- 2015-12-21 PH PH1/2017/550030A patent/PH12017550030B1/en unknown
- 2015-12-21 UA UAA201707648A patent/UA125492C2/uk unknown
- 2015-12-21 JP JP2017551985A patent/JP6858130B2/ja active Active
- 2015-12-21 KR KR1020177020292A patent/KR102715569B1/ko active Active
- 2015-12-21 EA EA201791361A patent/EA201791361A1/ru unknown
- 2015-12-21 WO PCT/NL2015/050893 patent/WO2016105190A1/en not_active Ceased
- 2015-12-21 SG SG11201705175RA patent/SG11201705175RA/en unknown
- 2015-12-21 CN CN201580076659.8A patent/CN107249618B/zh active Active
- 2015-12-21 MX MX2017008455A patent/MX374877B/es active IP Right Grant
- 2015-12-21 BR BR112017013521-3A patent/BR112017013521A2/pt not_active Application Discontinuation
- 2015-12-21 AU AU2015367900A patent/AU2015367900B2/en active Active
-
2017
- 2017-01-17 US US15/408,256 patent/US10183029B2/en active Active
- 2017-06-21 CL CL2017001640A patent/CL2017001640A1/es unknown
- 2017-06-21 IL IL253078A patent/IL253078B/en active IP Right Grant
- 2017-07-20 ZA ZA201704958A patent/ZA201704958B/en unknown
-
2020
- 2020-05-18 US US16/877,186 patent/US11752157B2/en active Active
-
2021
- 2021-01-08 JP JP2021002022A patent/JP7184935B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2017001640A1 (es) | Terapia con antagonista del receptor de oxitocina en la fase lútea para la implantación y embarazo en mujeres que se someten a tecnologías de reproducción asistida. | |
| CL2017000310A1 (es) | Anticuerpos anti tigit | |
| UY34750A (es) | ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?. | |
| TWD171866S (zh) | 腳踏車座墊（一） | |
| ECSP16012582A (es) | Compuestos heterocíclicos y métodos de uso | |
| CO2018012180A2 (es) | Métodos de tratamiento para enfermedades colestásicas y fibróticas | |
| UY36455A (es) | Antagonistas del receptor ep3 de prostaglandinas | |
| PL2982352T3 (pl) | Krążek szyjki macicy zawierający progesteron do długotrwałego, przedłużonego i ciągłego uwalniania, stosowany w celu zapobiegania przed przedwczesnym porodem | |
| MX2020011406A (es) | Metodos para aumentar el progreso genetico en una linea o raza de cerdo con celulas de esperma seleccionadas por sexo. | |
| MX2017001396A (es) | Metodos para mejorar el rendimiento miocardico en pacientes con cirugia de fontan que utilizan composiciones de udenafilo. | |
| MX2017001632A (es) | Mioinositol y probioticos, y uso de estos. | |
| TWD183042S (zh) | 馬桶 | |
| CL2018003188A1 (es) | Procedimiento para la preparación de cuerpos moldeados para la administración a animales. | |
| CR20150530A (es) | Derivados de espiroindolina como antagonistas del receptor de la hormona liberadora de gonadotropina | |
| AR120118A2 (es) | Anticuerpos anti tigit | |
| TWD187367S (zh) | 電池 | |
| TWD187368S (zh) | 電池 | |
| TWD186802S (zh) | 電池(二) | |
| TWD186495S (zh) | 動物用攜帶袋 | |
| GT201100010U (es) | Zeva | |
| ES1168633Y (es) | Anillo para reducir la sensibilidad en el glande del pene | |
| AR093987A1 (es) | Inmovilizador de manos para los deportes y la medicina | |
| TWD173294S (zh) | 馬桶 | |
| TWD173974S (zh) | 波士頓包 | |
| TWD169827S (zh) | 模型飛機之機體 |